Furthermore, the competitive inhibitor of IDH1 and IDH2, oxalomalate, inhibited HIF-1α-mediated VEGF expression through ROS-controlled E2F1 activity in retinal pigment epithelium cells and decreased the development of choroidal neovascularization in the mouse model of age-related macular degeneration, providing a novel therapeutic strategy for treating pathological angiogenesis through IDH inhibition [76]. The gene discussed is IDH1; the disease is age-related macular degeneration.